NRN1 and Alzheimer disease: Collective evidence supports the promise of NRN1 as a therapeutic target to enhance synaptic resilience mechanisms in preclinical AD (An et al., 2014; Choi et al., 2014; Hurst et al., 2023; Ng et al., 2023).